Aprea Therapeutics (NASDAQ: APRE) (@ApreaTX) / X

Aprea Therapeutics (NASDAQ: APRE)

112 posts

Aprea Therapeutics (NASDAQ: APRE)

@ApreaTX

Aprea (NASDAQ: $APRE) is developing innovative precision therapies for cancers with specific genetic alterations to potentially minimize damage to healthy cells

Doylestown, Pennsylvania

aprea.com

Joined September 2024

Aprea Therapeutics (NASDAQ: APRE)
@ApreaTX
Sep 11, 2024
In a recent @PharmExec feature by @PharmexecM, Oren Gilad of Aprea Therapeutics explains how synthetic lethality targets #cancer's genetic mutations, aiming for effective treatment with fewer side effects. bit.ly/475mo27 $APRE #CancerResearch #PrecisionMedicine
77
Aprea Therapeutics (NASDAQ: APRE)
@ApreaTX
Jun 25, 2025
New preclinical data for Aprea's next-generation WEE1 Inhibitor, APR-1051, demonstrate robust single agent activity and significant synergy with anti-PD-1 immunotherapy in HPV+ head and neck squamous cell carcinoma (HNSCC). Read more: bit.ly/4lkj0Gr $APRE
00:00
282
Aprea Therapeutics (NASDAQ: APRE)
@ApreaTX
Feb 18, 2025
Aprea is on a mission to increase the specificity and reduce the toxicity of DNA Damage Response (DDR) inhibitors to give cancer patients more choices. Learn about our therapeutic pipeline here: bit.ly/3WSYDq6 $APRE
00:00
690
Aprea Therapeutics (NASDAQ: APRE)
@ApreaTX
Dec 12, 2024
Dr. Anthony Tolcher, Investigator in the ongoing ABOYA-119 Phase 1/2a clinical trial, comments on the first patient being dosed at Dose Level 7 of ATRN-119 550 mg twice daily: bit.ly/3VCdBQH $APRE
00:00
2.1K
Aprea Therapeutics (NASDAQ: APRE)
@ApreaTX
Jun 26, 2025
"We are very encouraged by these early findings and see APR-1051 as a potentially promising addition to the therapeutic portfolio for treating HPV-associated head and neck cancers," said Drs. Abdullah Osman and Jeffrey Myers from The University of Texas @MDAndersonNews.
00:00
891
Aprea Therapeutics (NASDAQ: APRE)
@ApreaTX
Feb 24, 2025
Our world-class team of precision oncology experts is dedicated to advancing breakthrough therapeutics for patients with genetically defined cancers. Learn more about the Aprea leadership team here: bit.ly/40SsQqv $APRE
00:00
373
Aprea Therapeutics (NASDAQ: APRE)
@ApreaTX
Feb 5, 2025
“Our strong patent portfolio reflects our commitment to innovation and leadership in the field of DNA Damage Response (DDR) therapeutics," said Oren Gilad, Ph.D., Aprea CEO. Read more about Aprea's intellectual property portfolio: bit.ly/42GGvDC $APRE
00:00
281
Aprea Therapeutics (NASDAQ: APRE)
@ApreaTX
Mar 31, 2025
Replying to @ApreaTX
This is the first patient to be dosed in Cohort 5 of the ACESOT-1051 clinical trial. It is also the first patient to be enrolled in this important indication, following Aprea's Material Transfer Agreement with @MDAndersonNews. bit.ly/43yh9s1 $APRE #HNSCC
68
Aprea Therapeutics (NASDAQ: APRE)
@ApreaTX
Sep 12, 2024
Aprea Therapeutics discusses their progress of the two ongoing clinical studies and a third pre-clinical program, targeting specific #genetic mutations. Read more in this interview with @PHLBizJournal about how they’re advancing #precisionmedicine: bit.ly/3AYr5Pj $APRE
56
Aprea Therapeutics (NASDAQ: APRE)
@ApreaTX
Jun 25, 2025
Aprea Therapeutics today announced compelling new preclinical data and a preliminary clinical update for APR-1051, the Company’s next-generation oral WEE1 inhibitor, in human HPV+ HNSCC in collaboration with the world-renowned @MDAndersonNews. bit.ly/4lkj0Gr $APRE
00:00
183
Aprea Therapeutics (NASDAQ: APRE)
@ApreaTX
Feb 3, 2025
Eric Brown, Ph.D., Scientific Consultant for Aprea, presented at the 8th Annual DDR Inhibitors Summit in Boston last week, highlighting Aprea's development of DDR-targeting therapeutics to advance precision oncology. $APRE
196
Aprea Therapeutics (NASDAQ: APRE)
@ApreaTX
Mar 12, 2025
The goal of the research to be done under Aprea's agreement with @MDAndersonnews is to further characterize the potential of APR-1051 in HPV+ and HPV- #HNSCC and generate insights that could support future clinical development. Read more: bit.ly/3FkrXQw $APRE
00:00
395
Aprea Therapeutics (NASDAQ: APRE)
@ApreaTX
Jun 26, 2025
Oren Gilad, Ph.D., President and CEO of Aprea, emphasizes the significance of early-signs of clinical activity for APR-1051 in HPV+ #HNSCC, resulting from the ongoing research collaboration with renowned oncology leader @MDAndersonNews. Read more: bit.ly/4lkj0Gr $APRE
00:00
179
Aprea Therapeutics (NASDAQ: APRE)
@ApreaTX
Aug 12, 2025
"We are pleased with our progress in 2025, as emerging data from both of our lead programs demonstrate evidence of clinical activity,” said Oren Gilad, Ph.D., President and CEO. For key business updates and potential upcoming milestones: bit.ly/414Jx30 $APRE
00:00
120